Work

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy

Year: 2024

Type: article

Abstract: •Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid and lubricating drops.•Dehydrated amniotic membrane patch to treat MIRV related ocular events is a novel therapeutic option.

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2024.101547

Authors: Brittany File, Anjali Hari, Ling Bei

Institutions: University of California, Irvine Medical Center, MemorialCare Long Beach Medical Center, Long Beach Medical Center

Language: English

Topic: Drug-Induced Ocular Toxicity

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750